• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ischaemic stroke in New Zealand: an economic study.

作者信息

Scott W G, Scott H

出版信息

N Z Med J. 1994 Nov 9;107(989):443-6.

PMID:7970352
Abstract

AIM

To quantify and describe the annual cost of ischaemic stroke to New Zealand society during 1992.

METHODS

A prevalence or cross sectional approach employing incremental estimation was used to estimate costs from the perspective of society. The study used unit record hospital and mortality data.

RESULTS

Direct costs ranged from $93 million to $140 m and loss of production was between $6 m and $14 m. Total quantified costs were estimated to lie between $99 m and $154 m. Hospital and continuing care costs when combined make up 90% of all quantified costs.

CONCLUSION

Ischaemic stroke affects mainly older people many of whom are discharged into the community and require costly community support or continuing care. The combination of an ageing population, increasing survival rates and constant incidence rates will result in a substantial rise in the costs of continuing care and community support. Most of these costs are at present obscured because much of the care provided does not involve money payments and/or data are not recorded and collated on a national basis. Incorrect policy decisions will be made if the nonhospital costs of stroke are not taken into account.

摘要

相似文献

1
Ischaemic stroke in New Zealand: an economic study.
N Z Med J. 1994 Nov 9;107(989):443-6.
2
Economic cost of community-acquired pneumonia in New Zealand adults.新西兰成年人社区获得性肺炎的经济成本。
N Z Med J. 2004 Jun 18;117(1196):U933.
3
Cost of coronary heart disease in New Zealand.新西兰冠心病的成本。
N Z Med J. 1993 Aug 25;106(962):347-9.
4
Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.预测5年内心血管疾病和中风的人群水平风险降低对急性住院率的影响——一项试点研究。
Public Health. 2006 Dec;120(12):1140-8. doi: 10.1016/j.puhe.2006.10.012. Epub 2006 Nov 3.
5
Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina.阿根廷脑出血和缺血性中风的急性治疗费用。
Acta Neurol Scand. 2009 Apr;119(4):246-53. doi: 10.1111/j.1600-0404.2008.01094.x. Epub 2008 Sep 1.
6
Acute treatment costs of stroke in Brazil.巴西中风的急性治疗费用。
Neuroepidemiology. 2009;32(2):142-9. doi: 10.1159/000184747. Epub 2008 Dec 17.
7
Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.有特殊医疗需求且在医院综合初级保健诊所登记的儿童的医疗服务利用情况及费用
Pediatrics. 2005 Jun;115(6):e637-42. doi: 10.1542/peds.2004-2084.
8
Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs.纳米比亚艾滋病的经济和人口影响:成本快速评估
Int J Health Plann Manage. 1997 Oct-Dec;12(4):315-26. doi: 10.1002/(SICI)1099-1751(199710/12)12:4<315::AID-HPM492>3.0.CO;2-A.
9
Epidemiology of hospital-treated Salmonella infection; data from a national cohort over a ten-year period.医院治疗沙门氏菌感染的流行病学;来自一个全国队列十年期间的数据。
J Infect. 2009 Mar;58(3):175-81. doi: 10.1016/j.jinf.2009.01.002. Epub 2009 Feb 5.
10
The cost of campylobacteriosis in New Zealand in 1995.1995年新西兰弯曲杆菌病的成本。
N Z Med J. 1997 Jun 27;110(1046):222-4.

引用本文的文献

1
Effects of Repetitive Transcranial Magnetic Stimulation Over Trunk Motor Spot on Balance Function in Stroke Patients.重复经颅磁刺激躯干运动点对脑卒中患者平衡功能的影响
Ann Rehabil Med. 2016 Oct;40(5):826-834. doi: 10.5535/arm.2016.40.5.826. Epub 2016 Oct 31.
2
A literature review of indirect costs associated with stroke.一篇关于中风相关间接成本的文献综述。
J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1753-63. doi: 10.1016/j.jstrokecerebrovasdis.2014.02.017. Epub 2014 Jun 21.
3
The impact of neuropsychological deficits on functional stroke outcomes.
神经心理学缺陷对功能性卒中结局的影响。
Neuropsychol Rev. 2006 Jun;16(2):53-64. doi: 10.1007/s11065-006-9007-5. Epub 2006 Aug 9.
4
Long term cost-of-illness in stroke: an international review.中风的长期疾病成本:一项国际综述。
Pharmacoeconomics. 2002;20(12):813-25. doi: 10.2165/00019053-200220120-00002.
5
Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis.将欧洲卒中预防研究2(ESPS - 2)的研究结果应用于新西兰缺血性卒中成本分析。
Pharmacoeconomics. 1997 Dec;12(6):667-74. doi: 10.2165/00019053-199712060-00006.
6
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.塞利洛尔和阿替洛尔在高血压患者心血管疾病一级预防中的健康效益及成本效益预测模型
Pharmacoeconomics. 1997 Sep;12(3):384-408. doi: 10.2165/00019053-199712030-00010.
7
Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction.心力衰竭。使用SOLVD治疗试验的已发表结果对新西兰数据进行的决策分析。左心室功能障碍研究。
Pharmacoeconomics. 1996 Feb;9(2):156-67. doi: 10.2165/00019053-199609020-00007.
8
The use of drugs for cardioversion of recent onset atrial fibrillation and flutter. Focus on ibutilide.近期发作的心房颤动和心房扑动的药物复律治疗。重点关注伊布利特。
Drugs Aging. 1998 Jun;12(6):461-76. doi: 10.2165/00002512-199812060-00004.